Dyax Corp. to Participate in the Leerink Swann Global Healthcare Conference

  Dyax Corp. to Participate in the Leerink Swann Global Healthcare Conference

Business Wire

BURLINGTON, Mass. -- February 6, 2013

Dyax Corp. (NASDAQ: DYAX) announced today that executive management will
participate in the Leerink Swann Global Healthcare Conference, being held
February 13-14, 2013, at the Waldorf Astoria in New York City. Gustav
Christensen, President and Chief Executive Officer of Dyax, will present on
Thursday, February 14 at 11:00 AM (ET). Mr. Christensen will provide a
corporate update regarding the Company’s key value drivers – KALBITOR^®
(ecallantide) and the angioedema portfolio, as well as the Licensing and
Funded Research Program (LFRP).

This presentation will be webcast live and may be accessed by visiting the
Investor Relations section of the company website at www.dyax.com. The webcast
will also be available on the Dyax website for a limited period of time
following the conferences.

About Dyax

Dyax is a fully integrated biopharmaceutical company focused on the discovery,
development and commercialization of novel biotherapeutics for unmet medical
needs. The Company’s key value drivers are the KALBITOR^® (ecallantide)
business and the angioedema portfolio, as well as the Licensing and Funded
Research Program (LFRP).

Dyax developed KALBITOR on its own and, since February 2010, the Company has
been selling it in the United States for the treatment of acute attacks of
hereditary angioedema (HAE) in patients 16 years of age and older. Outside the
United States, the Company has established partnerships to obtain regulatory
approval for and commercialization of KALBITOR in certain markets and is
evaluating opportunities in others.

The Company is currently developing products to expand its angioedema
portfolio, including diagnostic strategies to identify plasma kallikrein
(bradykinin) mediated (PKM) angioedema and a therapeutic candidate, DX-2930,
for the prophylactic treatment of, HAE and other PKM angioedemas.

KALBITOR and DX-2930 were identified using Dyax’s patented phage display
technology, which rapidly selects compounds that bind with high affinity and
specificity to therapeutic targets. Dyax leverages this technology broadly
through the LFRP. This program has provided the Company a portfolio of product
candidates being developed by its licensees, which currently includes12
royalty and/or milestone bearing product candidates in various stages of
clinical development, including three in Phase 3 trials.

Dyax is headquartered in Burlington, Massachusetts. For additional information
about Dyax, please visit www.dyax.com.

Contact:

Dyax Corp.
Jennifer Robinson, 617-250-5741
Associate Director, Investor Relations and
Corporate Communications
jrobinson@dyax.com
 
Press spacebar to pause and continue. Press esc to stop.